Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of 0.11 is 108% above its 5-year average of -1.39, near the high end of its 5-year range (-3.52–0.43).
119.64% above its 12-month average of -0.56.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.16.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 31 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T20:13:31.036Z. Historical observations retain their original dates. Historical series through 2026-10-05.
EARNINGS PER SHARE (EPS)
0.11
EARNINGS PER SHARE (EPS) AVG TTM
-0.56
EARNINGS PER SHARE (EPS) AVG 3Y
-0.48
EARNINGS PER SHARE (EPS) AVG 5Y
-1.39
EARNINGS PER SHARE (EPS) AVG 10Y
-3.41
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+119.64%
CURRENT VS 3Y AVG
+122.92%
CURRENT VS 5Y AVG
+107.90%
CURRENT VS 10Y AVG
+103.23%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Spero Therapeutics, Inc.
Market Cap
$68.90M
Earnings Per Share (EPS)
0.11
TTM Avg
-0.56
3Y Avg
-0.48
5Y Avg
-1.39
Market Cap
$68.10M
Earnings Per Share (EPS)
2.68
TTM Avg
-1.38
3Y Avg
-6.44
5Y Avg
-7.90
Market Cap
$69.88M
Earnings Per Share (EPS)
-0.08
TTM Avg
0.13
3Y Avg
-0.17
5Y Avg
-0.10
Market Cap
$67.52M
Earnings Per Share (EPS)
-0.33
TTM Avg
-1.03
3Y Avg
-28.69
5Y Avg
-510.63
Market Cap
$70.63M
Earnings Per Share (EPS)
N/A
TTM Avg
-0.27
3Y Avg
-0.33
5Y Avg
-0.45
Market Cap
$71.23M
Earnings Per Share (EPS)
-0.50
TTM Avg
-0.75
3Y Avg
-1.17
5Y Avg
-1.06
Market Cap
$66.01M
Earnings Per Share (EPS)
-1.48
TTM Avg
-1.38
3Y Avg
-1.16
5Y Avg
-0.93
Market Cap
$65.87M
Earnings Per Share (EPS)
-55.66
TTM Avg
-39.81
3Y Avg
-97.72
5Y Avg
-154.19
Market Cap
$65.86M
Earnings Per Share (EPS)
-5.01
TTM Avg
-7.16
3Y Avg
-89.38
5Y Avg
-71.00
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | $68.90M | 0.11 | -0.56 | -0.48 | -1.39 |
| Fortress Biotech, Inc. (FBIO)vs › | $68.10M | 2.68 | -1.38 | -6.44 | -7.90 |
| Champions Oncology, Inc. (CSBR)vs › | $69.88M | -0.08 | 0.13 | -0.17 | -0.10 |
| iBio, Inc. (IBIO)vs › | $67.52M | -0.33 | -1.03 | -28.69 | -510.63 |
| Tiziana Life Sciences Ltd (TLSA)vs › | $70.63M | N/A | -0.27 | -0.33 | -0.45 |
| Gain Therapeutics, Inc. (GANX)vs › | $71.23M | -0.50 | -0.75 | -1.17 | -1.06 |
| XBiotech Inc. (XBIT)vs › | $66.01M | -1.48 | -1.38 | -1.16 | -0.93 |
| Gossamer Bio, Inc. (GOSS)vs › | $65.87M | -55.66 | -39.81 | -97.72 | -154.19 |
| Cingulate Inc. (CING)vs › | $65.86M | -5.01 | -7.16 | -89.38 | -71.00 |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $72.32M | -1.74 | -8.23 | -9.60 | -11.41 |
Trailing EPS (TTM)
$0.11
Forward EPS (Est.)
$-0.58
P/E Ratio
10.8
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | 0.15 |
| 2024-12-31 | -1.27 |
| 2023-12-31 | 0.43 |
| 2022-12-31 | -1.23 |
| 2021-12-31 | -2.91 |
| 2020-12-31 | -3.52 |
| 2019-12-31 | -3.31 |
| 2018-12-31 | -2.60 |
| 2017-12-31 | -17.82 |
| 2016-12-31 | -3.86 |
| 2015-12-31 | -1.54 |
